Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report’s recommendations. For more on The Globe’s disclaimers please read here. The following is excerpted from the report:

Q1 2018 Y/Y blended earnings growth estimates

  • TSX Composite (TSCX) = 12.1 per cent
  • Ex-energy = 13.6 per cent
  • Valeant Pharmaceuticals International Inc. (VRX-T) = 6.5 per cent
  • Healthcare ex-Valent = 62.7 per cent
  • TSX Composite ex-Valent = 12.1 per cent

Q1 2018 performance vs. earnings expectations

Sixty-six per cent of the TSX Composite companies have reported Q1 2018 EPS. Of the 162 companies in the index that have reported earnings to date for Q1 2018:

  • 43.8 per cent reported above analyst expectations
  • 40.1 per cent reported below analyst expectations

Revenue highlights

Q1 2018 Y/Y blended revenue growth estimates

  • TSX Composite = 9.6 per cent
  • Ex-energy = 7.4 per cent
  • Valeant Pharmaceuticals = -10.7 per cent
  • Healthcare ex-Valeant = 14.0 per cent
  • TSX Composite ex-Valeant = 9.8 per cent

Q1 2018 performance vs. revenue expectations

Of the TSX Composite companies that have reported revenue to date for Q1 2018:

Story continues below advertisement

  • 59.3 per cent reported above analyst expectations
  • 40.7 per cent reported below analyst expectations

Click here to see the full version of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.

Globe app users click here for the full report.

Read other research reports here.